Most Clicked AABB SmartBrief Stories


1. Stem cell researchers report reversal of multiple sclerosis symptoms

AABB SmartBrief | Mar 02, 2015

A U.K. study in the Journal of the American Medical Association found patients with multiple sclerosis regained mobility following stem cell therapy. The patients' stem cells were collected and reinfused after chemotherapy to effectively reset their immune systems, according to the researchers. The study did not include a control group. Telegraph (London) (tiered subscription model), The (03/01)


2. Study examines surgical blood tests and need for transfusions

AABB SmartBrief | Mar 05, 2015

A study in The Annals of Thoracic Surgery found that heart surgery patients who had more blood tests were more likely to receive blood transfusions. Cleveland Clinic researchers analyzed data involving nearly 1,900 patients treated in 2012. In total, 221,000 blood tests were conducted for the study group, and the median volume of blood taken for the tests was 454 milliliters per hospital stay. HealthDay News (03/02)


3. Study projects increasing rates of chronic kidney disease

AABB SmartBrief | Mar 04, 2015

Fifty-four percent of people ages 30 to 49 are likely to develop chronic kidney disease at some point during their lives. More than 13% of adults ages 30 and older have CKD, and that figure is expected to reach 14.4% by 2020 and jump to 16.7% a decade later, according to a study in the American Journal of Kidney Diseases. Researchers said they were surprised by the findings and expressed hope the study would draw more attention to the condition and spark research. Medical News Today (03/02)


4. Upcoming audioconference discusses clinical practice guidelines for platelet transfusions

AABB SmartBrief | Feb 27, 2015

On Tuesday, March 3, AABB's audioconference, "Guidelines for Platelet Use," will discuss the November 2014 publication of clinical practice guidelines for platelet transfusions. Based on a systematic review of available data and developed pursuant to the widely recognized GRADE methodology, these evidence-based guidelines are designed to provide clinicians with valuable guidance regarding when and at what dose to transfuse platelets in a variety of patient populations. These populations include individuals with hypoproliferative thrombocytopenia and patients undergoing procedures such as elective central venous catheter placement, lumbar puncture and major, elective, non-neuraxial surgery and coronary artery bypass graft surgery. Blank (02/27)


5. Stem cell study examines prevalence of leukemia-related mutations by age

AABB SmartBrief | Feb 27, 2015

Researchers in the U.K. have found that about 20% of people ages 50 to 60 and more than 70% of people older than 90 had leukemia-related mutations in blood stem cells, according to a study in the journal Cell Reports. The findings were based on an analysis of cell samples from 4,200 healthy people. HealthDay News (02/26) Independent (London) (tiered subscription model), The (02/26)


6. Experimental bone replacement technique is based on autologous stem cells

AABB SmartBrief | Mar 03, 2015

EpiBone is working to develop bone replacement techniques that use autologous stem cells grown on a matrix of decellularized animal-derived bone. The company has studied the method in pigs. Bloomberg (03/02)


7. Strains of HIV-1 originated from gorillas, study finds

AABB SmartBrief | Mar 03, 2015

A study in the Proceedings of the National Academy of Sciences found that the source of HIV-1 groups O and P originated with gorillas in Cameroon. Researchers said the transmission was most likely due to infected blood or tissue exposure during hunting for and butchering of bushmeat. The HIV-1 group O, the second most common HIV-1 strain, has infected about 100,000 people across Cameroon, Gabon, Nigeria and neighboring countries, while only two cases have been documented of HIV-1 group P infection. Reuters (03/02)


8. Portola's factor Xa inhibitor antidote receives FDA orphan designation

AABB SmartBrief | Feb 27, 2015

Portola Pharmaceuticals' experimental drug andexanet alfa received orphan drug status from the FDA for use in reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing serious uncontrolled bleeding or needing emergency surgical procedures. The drug is being evaluated in two late-stage trials. Healio (free registration) (02/26)


9. AABB submits comments on HCT/P draft guidances

AABB SmartBrief | Mar 02, 2015

AABB submitted comments to FDA on Monday, February 23, on two draft guidance documents related to human cells, tissues and cellular and tissue-based products, or HCT/Ps. Regarding the first guidance, "Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products," AABB's comments request clarification for a number of topics, including how to define the term "main function" as used in the phrase "The main function of the HCT/P," and the regulatory treatment of certain processes and tissue-based products. In addition, AABB recommends that FDA remove bone marrow aspirate as an example of tissues considered cells or nonstructural tissues. AABB expressed appreciation to FDA for publishing a second draft guidance, "Human Cells, Tissues, and Cellular and Tissue-Based Products from Adipose Tissue: Regulatory Considerations," which clarifies regulatory considerations for the manufacture and use of HCT/Ps from adipose tissue. Blank (03/02)


10. WHO expert panel to consider mass vaccination against Ebola

AABB SmartBrief | Mar 02, 2015

The World Health Organization's expert advisory panel on immunization could recommend as soon as August whether to commence the mass use of vaccinations against Ebola. "We know the vaccines are safe, we know they produce a good immunogenic response in humans, but we don't know if they are effective when you actually have disease in community," said spokeswoman Margaret Harris of the WHO. Reuters (02/27)




Sign up for AABB SmartBrief



Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge. Learn more